
Opinion|Videos|March 6, 2024
Staging Practices for Chronic Graft-vs-Host Disease
Hana Safah, MD, reviews the NIH staging system for graft-vs-host disease and discusses the importance of staging in determining prognosis and informing treatment decisions.
Advertisement
Episodes in this series

Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5



